Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Inhaled BAY 1211163 in ARDS
NCT04609943Phase 1Terminated
- Sponsor
- Bayer
- Start
- Nov 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BAY1211163 in acute respiratory distress syndrome (ARDS), sponsored by Bayer. Primary endpoints: Treatment Emergent Adverse Events up to 9 days and Dose Limiting Events. Started Nov 2020; status: terminated.
02
Drugs
BAY1211163
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04609943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609943.